9/6
08:08 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
High
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
8/30
11:40 am
btai
Rating for BTAI
Low
Report
Rating for BTAI